Amphastar Pharmaceuticals (NASDAQ:AMPH) has been upgraded to Buy from Hold at Needham after getting FDA approval for its ...

US generics major Viatris has won US Food and Drug Administration (FDA) approval for iron sucrose injection, USP, an ...

Viatris receives US FDA approval for generic iron sucrose injection to treat IDA in chronic kidney disease: Pittsburgh Tuesday, August 12, 2025, 18:00 Hrs [IST] Viatris Inc., a gl ...

Viatris (NASDAQ:VTRS) announced on Monday that the U.S. FDA has approved its Iron Sucrose Injection, USP, as a generic ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

Among Indian generics makers, Iron Sucrose had been considered a key pipeline product for Dr. Reddy’s Laboratories and ...

Amphastar Pharma’s iron sucrose injection receives US FDA approval to treat iron deficiency anaemia in patients with CKD: Rancho Cucamonga, California Tuesday, August 12, 2025, ...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

Sucrose provides plants with more than energy. It acts as a temperature sensor, signaling growth in warm conditions.